PEMIGATINIB

Details

Stereochemistry	ACHIRAL
Molecular Formula	C24H27F2N5O4
Molecular Weight	487.4991
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CCN1C(=O)N(CC2=CN=C3NC(CN4CCOCC4)=CC3=C12)C5=C(F)C(OC)=CC(OC)=C5F

InChI

InChIKey=HCDMJFOHIXMBOV-UHFFFAOYSA-N

InChI=1S/C24H27F2N5O4/c1-4-30-21-14(11-27-23-16(21)9-15(28-23)13-29-5-7-35-8-6-29)12-31(24(30)32)22-19(25)17(33-2)10-18(34-3)20(22)26/h9-11H,4-8,12-13H2,1-3H3,(H,27,28)

HIDE SMILES / InChI

Molecular Formula	C24H27F2N5O4
Molecular Weight	487.4991
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: https://pubmed.ncbi.nlm.nih.gov/32315352|https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/213736Orig1s000MultidisciplineR.pdf

Pemigatinib, an oral kinases inhibitor, was approved under the brand name PEMAZYRE for the treatment of adults with previously treated, unresectable locally advanced, or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (FGFR2) fusion. The FDA-approved indication for pemigatinib was granted under accelerated approval based on the overall response rate and duration of response in pre-marketing clinical trials. The drug inhibited FGFR1-3 phosphorylation and signaling and decreased cell viability in cancer cell lines with activating FGFR amplification and fusions that resulted in constitutive activation of FGFR signaling.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Potency
Fibroblast growth factor receptor 1 46 Target ID: P11362\|\|\|Q14307\|\|\|Q9UDF2 Gene ID: 2260.0 Gene Symbol: FGFR1 Target Organism: Homo sapiens (Human) Sources: https://pubmed.ncbi.nlm.nih.gov/32315352 \| https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213736s000lbl.pdf	Inhibitor 8504	0.4 nM [IC50]
Fibroblast growth factor receptor 2 25 Target ID: P21802\|\|\|Q14301\|\|\|Q1KHY5\|\|\|Q9NZU3\|\|\|Q9UIH8 Gene ID: 2263.0 Gene Symbol: FGFR2 Target Organism: Homo sapiens (Human) Sources: https://pubmed.ncbi.nlm.nih.gov/32315352 \| https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213736s000lbl.pdf	Inhibitor 8504	0.5 nM [IC50]
Fibroblast growth factor receptor 3 32 Target ID: P22607 Gene ID: 2261.0 Gene Symbol: FGFR3 Target Organism: Homo sapiens (Human) Sources: https://pubmed.ncbi.nlm.nih.gov/32315352 \| https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213736s000lbl.pdf	Inhibitor 8504	1.0 nM [IC50]

Conditions

Condition	Modality	Targets	Highest Phase	Product
cholangiocarcinoma 1 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213736s000lbl.pdf	Primary		Approved 8583	PEMAZYRE Approved Use PEMAZYRE is a kinase inhibitor indicated for the treatment of adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (FGFR2) fusion

C_max

Value	Dose	Co-administered	Analyte	Population
236 nM DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213736s000lbl.pdf	13.5 mg 1 times / day steady-state, oral dose: 13.5 mg route of administration: Oral experiment type: STEADY-STATE co-administered:		PEMIGATINIB plasma	Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: UNKNOWN

AUC

Value	Dose	Co-administered	Analyte	Population
2620 nM × h DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213736s000lbl.pdf	13.5 mg 1 times / day steady-state, oral dose: 13.5 mg route of administration: Oral experiment type: STEADY-STATE co-administered:		PEMIGATINIB plasma	Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: UNKNOWN

T_1/2

Value	Dose	Co-administered	Analyte	Population
15.4 h DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213736s000lbl.pdf	13.5 mg 1 times / day steady-state, oral dose: 13.5 mg route of administration: Oral experiment type: STEADY-STATE co-administered:		PEMIGATINIB plasma	Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: UNKNOWN

Sample Use Guides

In Vivo Use Guide

The recommended dosage is 13.5 mg orally once daily for 14 consecutive days followed by 7 days off therapy, in 21-day cycles. Continue treatment until disease progression or unacceptable toxicity occurs

Route of Administration: Oral

Substance Class	Chemical Created by `admin` on `Tue Apr 01 18:17:36 GMT 2025` Edited by `admin` on `Tue Apr 01 18:17:36 GMT 2025`
Record UNII	Y6BX7BL23K
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

2H-PYRROLO(3',2':5,6)PYRIDO(4,3-D)PYRIMIDIN-2-ONE, 3-(2,6-DIFLUORO-3,5-DIMETHOXYPHENYL)-1-ETHYL-1,3,4,7-TETRAHYDRO-8-(4-MORPHOLINYLMETHYL)-

Preferred Name

English

PEMIGATINIB

Official Name

English

3-(2,6-DIFLUORO-3,5-DIMETHOXYPHENYL)-1-ETHYL-8-(MORPHOLIN-4-YLMETHYL)-1,3,4,7-TETRAHYDRO-2H-PYRROLO(3',2':5,6)PYRIDO(4,3-D)PYRIMIDIN-2-ONE

Systematic Name

English

INCB-054828

Common Name

English

PEMIGATINIB [USAN]

Common Name

English

PEMIGATINIB [JAN]

Common Name

English

Pemigatinib [WHO-DD]

Common Name

English

PEMIGATINIB [ORANGE BOOK]

Common Name

English

FGFR INHIBITOR INCB054828

Common Name

English

pemigatinib [INN]

Common Name

English

PEMIGATINIB [MI]

Common Name

English

INCB054828

Code

English

PEMAZYRE

Brand Name

English

Classification Tree Code System Code

FDA ORPHAN DRUG

624117